Published in J Virol on October 01, 2003
Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 1.88
The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology (2005) 1.67
The diversity of retrotransposons and the properties of their reverse transcriptases. Virus Res (2008) 1.51
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J Virol (2004) 0.91
Role of integrase in reverse transcription of the Saccharomyces cerevisiae retrotransposon Ty1. Eukaryot Cell (2005) 0.91
Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology (2010) 0.90
Cooperation between reverse transcriptase and integrase during reverse transcription and formation of the preintegrative complex of Ty1. Eukaryot Cell (2006) 0.86
Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells. PLoS One (2013) 0.84
Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res (1998) 96.63
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res (1997) 13.48
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Construction and analysis of deletion mutations in the pol gene of Moloney murine leukemia virus: a new viral function required for productive infection. Cell (1984) 7.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Ribbons. Methods Enzymol (1997) 5.83
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Complementation between HIV integrase proteins mutated in different domains. EMBO J (1993) 3.32
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol (1996) 2.82
Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol (1994) 2.26
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology (1993) 1.83
Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol (1995) 1.77
Analysis of mutations in the integration function of Moloney murine leukemia virus: effects on DNA binding and cutting. J Virol (1990) 1.75
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol (1996) 1.71
Analysis of human immunodeficiency virus type 1 integrase mutants. Virology (1995) 1.58
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli. J Virol (1986) 1.55
Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med (2001) 1.46
Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol (1996) 1.44
Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J Virol (1997) 1.27
Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology (1996) 1.26
Mutational analysis of the carboxyl terminus of the Moloney murine leukemia virus integration protein. J Virol (1991) 1.21
HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett (2001) 1.17
Expression of human immunodeficiency virus type 1 reverse transcriptase in trans during virion release and after infection. J Virol (1996) 1.10
Moloney murine leukemia virus integrase protein augments viral DNA synthesis in infected cells. J Virol (2001) 1.03
The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein. J Virol (2002) 1.02
Production of trans-lentiviral vector with predictable safety. Methods Mol Med (2003) 1.02
Mutations in nonconserved domains of Ty3 integrase affect multiple stages of the Ty3 life cycle. J Virol (1999) 1.00
Ty3 integrase is required for initiation of reverse transcription. J Virol (2002) 0.98
Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. Biochem J (2002) 0.95
Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase. J Virol (1999) 0.87
Targeting human immunodeficiency virus (HIV) type 2 integrase protein into HIV type 1. J Virol (1999) 0.84
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
The interferon-inducible p47 (IRG) GTPases in vertebrates: loss of the cell autonomous resistance mechanism in the human lineage. Genome Biol (2005) 4.21
Pattern of sequence variation across 213 environmental response genes. Genome Res (2004) 3.93
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet (2008) 3.25
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 3.12
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
Crystal structure of the cytoskeleton-associated protein glycine-rich (CAP-Gly) domain. J Biol Chem (2002) 3.01
Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol (2012) 2.77
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem (2008) 2.55
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet (2003) 2.07
Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry (2012) 2.02
Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat (2009) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res (2009) 1.84
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol (2010) 1.81
Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet (2009) 1.80
Cystin localizes to primary cilia via membrane microdomains and a targeting motif. J Am Soc Nephrol (2009) 1.79
A strong signature of balancing selection in the 5' cis-regulatory region of CCR5. Proc Natl Acad Sci U S A (2002) 1.78
Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst (2007) 1.78
Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One (2010) 1.73
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A (2005) 1.67
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol (2013) 1.63
A soma-to-germline transformation in long-lived Caenorhabditis elegans mutants. Nature (2009) 1.63
Independent evolution of bitter-taste sensitivity in humans and chimpanzees. Nature (2006) 1.59
Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol (2004) 1.56
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55
Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol (2003) 1.51
Fine-scaled human genetic structure revealed by SNP microarrays. Genome Res (2009) 1.48
Toward a more uniform sampling of human genetic diversity: a survey of worldwide populations by high-density genotyping. Genomics (2010) 1.47
Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res (2006) 1.42
The Southeast Collaboratory for Structural Genomics: a high-throughput gene to structure factory. Acc Chem Res (2003) 1.39
The Ess1 prolyl isomerase is required for transcription termination of small noncoding RNAs via the Nrd1 pathway. Mol Cell (2009) 1.35
EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. Blood (2007) 1.33
Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway. J Virol (2004) 1.32
DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord (2009) 1.31
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol (2012) 1.27
Elongated fibrillar structure of a streptococcal adhesin assembled by the high-affinity association of alpha- and PPII-helices. Proc Natl Acad Sci U S A (2010) 1.27
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol (2009) 1.27
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord (2010) 1.24
DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol (2008) 1.22
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Genome degeneration and adaptation in a nascent stage of symbiosis. Genome Biol Evol (2014) 1.18
Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS (2009) 1.16
Gene expression profiling reveals unique pathways associated with differential severity of lyme arthritis. J Immunol (2006) 1.15
GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol (2010) 1.15
Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat (2011) 1.13
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol (2012) 1.13
A novel human-infection-derived bacterium provides insights into the evolutionary origins of mutualistic insect-bacterial symbioses. PLoS Genet (2012) 1.12
Prolyl isomerases in yeast. Front Biosci (2004) 1.10
Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5. Am J Hum Genet (2004) 1.10
New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS (2009) 1.09
Common variant of human NEDD4L activates a cryptic splice site to form a frameshifted transcript. J Hum Genet (2002) 1.09
Autosomal recessive inheritance of classic Bethlem myopathy. Neuromuscul Disord (2009) 1.09
Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscul Disord (2013) 1.08
Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses (2010) 1.08
Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry (2012) 1.08
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol (2010) 1.07
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses (2007) 1.07
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat (2009) 1.03
Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol (2010) 1.02
Production of trans-lentiviral vector with predictable safety. Methods Mol Med (2003) 1.02
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med (2010) 1.02